Literature DB >> 23401728

Peculiarities in the Diagnosis Approach of MDS /MPN-U Patients.

Irina Triantafyllidis1, Anca Ciobanu, Oana Stanca, Cecilia Draghici, Silvana Angelescu, Eliza Tapelea.   

Abstract

The most recent WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues describes a set of diseases framed as the MDS / MPN (myelodysplastic / chronic myeloproliferative syndromes). There are four subtypes comprised in this category: chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, atypical chronic myeloid leukemia and unclassifiable MDS / MPN. They combine both myelodysplastic and myeloproliferative features. Although the unclassifiable MDS/ MPN subtype specifically associates the myelodysplastic and myeloproliferative features, it does not meet the criteria defining the first 3 subtypes. The RARS-T subtype (refractory anemia with ringed sideroblasts associated with marked thrombocytosis) is included in the MDS / MPN-U as a temporary entity. There are two cases described in this article: one diagnosed with RARS-T and one with MDS / MPN-U. Both cases evolved towards acute myeloid leukemia.

Entities:  

Year:  2012        PMID: 23401728      PMCID: PMC3557427     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  3 in total

Review 1.  Myelodysplastic/myeloproliferative neoplasms.

Authors:  Mario Cazzola; Luca Malcovati; Rosangela Invernizzi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  The role of JAK2 mutations in RARS and other MDS.

Authors:  Eva Hellström-Lindberg; Mario Cazzola
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

Review 3.  Cytogenetic features in myelodysplastic syndromes.

Authors:  Detlef Haase
Journal:  Ann Hematol       Date:  2008-04-15       Impact factor: 3.673

  3 in total
  1 in total

1.  Routine blood examinations combined with morphological analysis for the diagnosis of myelodysplastic/myeloproliferative neoplasms.

Authors:  Huanling Wu; Hui Sun; Zhifen Zhang; Xiangli Li; Yuantang Li; Li Li; Rui Xu; Zie Wang; Wenjun Tian
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.